#United States #Cambridge #Acute Kidney Injury #Vincere Biosciences #USP30 inhibitor

Vincere Biosciences Awarded $2.7 Million NIH Grant

Vincere Biosciences has recently secured a prestigious grant totaling $2.7 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This funding, part of the Small Business Innovation Research (SBIR) Phase II award, aims to advance the company's novel USP30 inhibitor designed to treat acute kidney injury (AKI). This financial support highlights the growing recognition of the urgency to address kidney illnesses, which impact over 13 million people globally each year.

The Challenge of Acute Kidney Injury

Acute kidney injury is a sudden decline in kidney function that can result from various factors such as ischemia, major surgeries, and exposure to harmful medications. Often overlooked, AKI poses a significant clinical burden and can lead to chronic kidney disease (CKD) if not effectively addressed. Current treatment methods for AKI remain limited—primarily supportive care—underscoring the need for innovative therapeutic solutions.

The NIDDK grant will enable Vincere to conduct crucial safety studies that are required for advancing its USP30 inhibitor toward an Investigational New Drug (IND) application. This development is not only essential for launching the new treatment into clinical trials but also represents a step forward in tackling the longstanding gaps in AKI treatments.

Targeting Mitochondrial Dysfunction

Vincere's innovative approach focuses on mitochondrial dysfunction—a major contributor to kidney injury. The company's USP30 inhibitor acts on mitophagy, the cellular process that removes damaged mitochondria. By effectively inhibiting USP30, which negatively regulates this process, Vincere aims to enhance mitochondrial recovery and promote the healing of injured kidney tissue.

Dr. Spring Behrouz, the co-founder and CEO of Vincere, expressed her enthusiasm for this research direction, stating, "While we formed Vincere to seek disease-modifying therapies for Parkinson's, I've always been intrigued by the data's potential to benefit other energy-dependent organs like the kidneys." This holistic perspective captures the essence of Vincere’s mission to explore the interconnectedness of various diseases associated with aging and cellular health.

Comprehensive Development Program

The grant will significantly bolster Vincere's IND-enabling program, which includes toxicology studies and safety assessments necessary for the phase of human clinical trials. These studies will thoroughly evaluate the safety of the USP30 inhibitor and its potential effects on various biological systems, including cardiovascular and central nervous system responses. Successful completion of these studies will pave the way for seeking IND approval and subsequent evaluations in human patients, a crucial phase in making innovative treatments available to those in need.

It's noteworthy that Vincere's developments do not stop at AKI. The firm also ventures in treating Parkinson's disease with a separate CNS-penetrant USP30 inhibitor supported by another substantial grant. This dual focus illustrates the versatility and broad applicability of the company's research initiatives.

Andy Lee, co-founder and CBO of Vincere, added, "Our computational biology platform aggregates knowledge across different therapeutic areas, enabling us to identify potential relationships that could lead to breakthroughs. We believe in a broad exploratory approach followed by strong commitment to data-driven decisions, ensuring our therapies align effectively with the needs of patients."

About Vincere Biosciences

Based in Cambridge, Massachusetts, Vincere Biosciences specializes in pioneering therapeutics that address the intersection of aging and disease. Through innovative computational methods and cutting-edge biology, the company aims to tackle fundamental issues in age-related conditions such as Parkinson's disease and acute kidney injury. With a growing portfolio supported by significant grants, Vincere is dedicated to improving patient outcomes through transformative health solutions.

For more information, you can visit Vincere Biosciences.